SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-260585
Filing Date
2020-10-01
Accepted
2020-10-01 08:42:02
Documents
15
Period of Report
2020-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63774d8k.htm   iXBRL 8-K 40390
2 EX-99.1 d63774dex991.htm EX-99.1 76840
3 EX-99.3 d63774dex993.htm EX-99.3 31712
7 GRAPHIC g63774g1001105156512.jpg GRAPHIC 1630
  Complete submission text file 0001193125-20-260585.txt   313002

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20201001.xsd EX-101.SCH 3093
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20201001_lab.xml EX-101.LAB 18138
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20201001_pre.xml EX-101.PRE 11423
8 EXTRACTED XBRL INSTANCE DOCUMENT d63774d8k_htm.xml XML 3422
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 201214541
SIC: 2834 Pharmaceutical Preparations